APO Research
Talk to an analyst

APO RESEARCH · REPORT

General Anxiety Disorder Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global General Anxiety Disorder Therapeutics Market Analysis and Forecast 2026-2032

26 December 2025199 pages

Choose your research edition.

Industry ResearchGeneral Anxiety Disorder Therapeutics Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal General Anxiety Disorder Therapeutics Industry Growth and Trends Forecast to 203264 pages · $3,450 USDMarket StructureGlobal General Anxiety Disorder Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032178 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal General Anxiety Disorder Therapeutics Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal General Anxiety Disorder Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global General Anxiety Disorder Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for General Anxiety Disorder Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for General Anxiety Disorder Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for General Anxiety Disorder Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for General Anxiety Disorder Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of General Anxiety Disorder Therapeutics include Bionomics Limited, Edgemont Pharmaceuticals, LLC and H. Lundbeck A/S, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for General Anxiety Disorder Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of General Anxiety Disorder Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for General Anxiety Disorder Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the General Anxiety Disorder Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global General Anxiety Disorder Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for General Anxiety Disorder Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

General Anxiety Disorder Therapeutics Segment by Company

Bionomics Limited

Edgemont Pharmaceuticals, LLC

H. Lundbeck A/S

General Anxiety Disorder Therapeutics Segment by Type

Itriglumide

Tedatioxetine

EDG-004

Others

General Anxiety Disorder Therapeutics Segment by Application

Clinic

Hospital

Others

General Anxiety Disorder Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global General Anxiety Disorder Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of General Anxiety Disorder Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of General Anxiety Disorder Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of General Anxiety Disorder Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of General Anxiety Disorder Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, General Anxiety Disorder Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global General Anxiety Disorder Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Itriglumide Major Player Table 3. Tedatioxetine Major Player Table 4. EDG-004 Major Player Table 5. Others Major Player Table 6. Global General Anxiety Disorder Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Clinic Major Player Table 8. Hospital Major Player Table 9. Others Major Player Table 10. General Anxiety Disorder Therapeutics Industry Trends Table 11. General Anxiety Disorder Therapeutics Industry Drivers Table 12. General Anxiety Disorder Therapeutics Industry Opportunities and Challenges Table 13. General Anxiety Disorder Therapeutics Industry Restraints Table 14. Global General Anxiety Disorder Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global General Anxiety Disorder Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 16. Global General Anxiety Disorder Therapeutics Market Share by Region (2021-2026) Table 17. Global General Anxiety Disorder Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 18. Global General Anxiety Disorder Therapeutics Market Share by Region (2027-2032) Table 19. Global General Anxiety Disorder Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 20. Global General Anxiety Disorder Therapeutics Revenue Market Share by Players (2021-2026) Table 21. Global General Anxiety Disorder Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global General Anxiety Disorder Therapeutics Key Players Headquarters & Area Served Table 23. Global General Anxiety Disorder Therapeutics Players, Product Type & Application Table 24. Global General Anxiety Disorder Therapeutics Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global General Anxiety Disorder Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global General Anxiety Disorder Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global General Anxiety Disorder Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 29. Global General Anxiety Disorder Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 30. Global General Anxiety Disorder Therapeutics Revenue Market Share by Type (2021-2026) Table 31. Global General Anxiety Disorder Therapeutics Revenue Market Share by Type (2027-2032) Table 32. Global General Anxiety Disorder Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global General Anxiety Disorder Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 34. Global General Anxiety Disorder Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 35. Global General Anxiety Disorder Therapeutics Revenue Market Share by Application (2021-2026) Table 36. Global General Anxiety Disorder Therapeutics Revenue Market Share by Application (2027-2032) Table 37. Bionomics Limited Company Information Table 38. Bionomics Limited Business Overview Table 39. Bionomics Limited General Anxiety Disorder Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Bionomics Limited General Anxiety Disorder Therapeutics Product Portfolio Table 41. Bionomics Limited Recent Development Table 42. Edgemont Pharmaceuticals, LLC Company Information Table 43. Edgemont Pharmaceuticals, LLC Business Overview Table 44. Edgemont Pharmaceuticals, LLC General Anxiety Disorder Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Edgemont Pharmaceuticals, LLC General Anxiety Disorder Therapeutics Product Portfolio Table 46. Edgemont Pharmaceuticals, LLC Recent Development Table 47. H. Lundbeck A/S Company Information Table 48. H. Lundbeck A/S Business Overview Table 49. H. Lundbeck A/S General Anxiety Disorder Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. H. Lundbeck A/S General Anxiety Disorder Therapeutics Product Portfolio Table 51. H. Lundbeck A/S Recent Development Table 52. North America General Anxiety Disorder Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 53. North America General Anxiety Disorder Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 54. North America General Anxiety Disorder Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 55. North America General Anxiety Disorder Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 56. North America General Anxiety Disorder Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 57. North America General Anxiety Disorder Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 58. North America General Anxiety Disorder Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 59. Europe General Anxiety Disorder Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 60. Europe General Anxiety Disorder Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 61. Europe General Anxiety Disorder Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 62. Europe General Anxiety Disorder Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 63. Europe General Anxiety Disorder Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 64. Europe General Anxiety Disorder Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 65. Europe General Anxiety Disorder Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 66. China General Anxiety Disorder Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 67. China General Anxiety Disorder Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 68. China General Anxiety Disorder Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 69. China General Anxiety Disorder Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 70. Asia General Anxiety Disorder Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 71. Asia General Anxiety Disorder Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 72. Asia General Anxiety Disorder Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 73. Asia General Anxiety Disorder Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 74. Asia General Anxiety Disorder Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 75. Asia General Anxiety Disorder Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 76. Asia General Anxiety Disorder Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 77. SAMEA General Anxiety Disorder Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 78. SAMEA General Anxiety Disorder Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 79. SAMEA General Anxiety Disorder Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 80. SAMEA General Anxiety Disorder Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 81. SAMEA General Anxiety Disorder Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 82. SAMEA General Anxiety Disorder Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 83. SAMEA General Anxiety Disorder Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 84. Research Programs/Design for This Report Table 85. Authors List of This Report Table 86. Secondary Sources Table 87. Primary Sources List of Figures Figure 1. General Anxiety Disorder Therapeutics Image Figure 2. Global General Anxiety Disorder Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global General Anxiety Disorder Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Itriglumide Image Figure 5. Tedatioxetine Image Figure 6. EDG-004 Image Figure 7. Others Image Figure 8. Global General Anxiety Disorder Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global General Anxiety Disorder Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 10. Clinic Image Figure 11. Hospital Image Figure 12. Others Image Figure 13. Global General Anxiety Disorder Therapeutics Market Size (US$ Million) & (2021-2032) Figure 14. Global General Anxiety Disorder Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global General Anxiety Disorder Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global General Anxiety Disorder Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global General Anxiety Disorder Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global General Anxiety Disorder Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global General Anxiety Disorder Therapeutics Revenue Market Share by Type (2021-2032) Figure 21. Global General Anxiety Disorder Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global General Anxiety Disorder Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global General Anxiety Disorder Therapeutics Revenue Market Share by Application (2021-2032) Figure 24. North America General Anxiety Disorder Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America General Anxiety Disorder Therapeutics Revenue Share by Type (2021-2032) Figure 26. North America General Anxiety Disorder Therapeutics Revenue Share by Application (2021-2032) Figure 27. North America General Anxiety Disorder Therapeutics Revenue Share by Country (2021-2032) Figure 28. United States General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe General Anxiety Disorder Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe General Anxiety Disorder Therapeutics Revenue Share by Type (2021-2032) Figure 33. Europe General Anxiety Disorder Therapeutics Revenue Share by Application (2021-2032) Figure 34. Europe General Anxiety Disorder Therapeutics Revenue Share by Country (2021-2032) Figure 35. Germany General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China General Anxiety Disorder Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China General Anxiety Disorder Therapeutics Revenue Share by Type (2021-2032) Figure 45. China General Anxiety Disorder Therapeutics Revenue Share by Application (2021-2032) Figure 46. Asia General Anxiety Disorder Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia General Anxiety Disorder Therapeutics Revenue Share by Type (2021-2032) Figure 48. Asia General Anxiety Disorder Therapeutics Revenue Share by Application (2021-2032) Figure 49. Asia General Anxiety Disorder Therapeutics Revenue Share by Region (2021-2032) Figure 50. Japan General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA General Anxiety Disorder Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA General Anxiety Disorder Therapeutics Revenue Share by Type (2021-2032) Figure 58. SAMEA General Anxiety Disorder Therapeutics Revenue Share by Application (2021-2032) Figure 59. SAMEA General Anxiety Disorder Therapeutics Revenue Share by Country (2021-2032) Figure 60. Brazil General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt General Anxiety Disorder Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Itriglumide
  • Tedatioxetine
  • EDG-004
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Bionomics Limited
  • Edgemont Pharmaceuticals, LLC
  • H. Lundbeck A/S

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 General Anxiety Disorder Therapeutics Market by Type
  3. 1.2.1 Global General Anxiety Disorder Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Itriglumide
  5. 1.2.3 Tedatioxetine
  6. 1.2.4 EDG-004
  7. 1.2.5 Others
  8. 1.3 General Anxiety Disorder Therapeutics Market by Application
  9. 1.3.1 Global General Anxiety Disorder Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Clinic
  11. 1.3.3 Hospital
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 General Anxiety Disorder Therapeutics Market Dynamics
  1. 2.1 General Anxiety Disorder Therapeutics Industry Trends
  2. 2.2 General Anxiety Disorder Therapeutics Industry Drivers
  3. 2.3 General Anxiety Disorder Therapeutics Industry Opportunities and Challenges
  4. 2.4 General Anxiety Disorder Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global General Anxiety Disorder Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global General Anxiety Disorder Therapeutics Growth Trends by Region
  3. 3.2.1 Global General Anxiety Disorder Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global General Anxiety Disorder Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global General Anxiety Disorder Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global General Anxiety Disorder Therapeutics Revenue by Players
  2. 4.1.1 Global General Anxiety Disorder Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global General Anxiety Disorder Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global General Anxiety Disorder Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global General Anxiety Disorder Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global General Anxiety Disorder Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global General Anxiety Disorder Therapeutics Players, Product Type & Application
  8. 4.5 Global General Anxiety Disorder Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global General Anxiety Disorder Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 General Anxiety Disorder Therapeutics Tier 1, Tier 2, and Tier 3
5 General Anxiety Disorder Therapeutics Market Size by Type
  1. 5.1 Global General Anxiety Disorder Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global General Anxiety Disorder Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global General Anxiety Disorder Therapeutics Revenue Market Share by Type (2021-2032)
6 General Anxiety Disorder Therapeutics Market Size by Application
  1. 6.1 Global General Anxiety Disorder Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global General Anxiety Disorder Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global General Anxiety Disorder Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Bionomics Limited
  2. 7.1.1 Bionomics Limited Company Information
  3. 7.1.2 Bionomics Limited Business Overview
  4. 7.1.3 Bionomics Limited General Anxiety Disorder Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Bionomics Limited General Anxiety Disorder Therapeutics Product Portfolio
  6. 7.1.5 Bionomics Limited Recent Developments
  7. 7.2 Edgemont Pharmaceuticals, LLC
  8. 7.2.1 Edgemont Pharmaceuticals, LLC Company Information
  9. 7.2.2 Edgemont Pharmaceuticals, LLC Business Overview
  10. 7.2.3 Edgemont Pharmaceuticals, LLC General Anxiety Disorder Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Edgemont Pharmaceuticals, LLC General Anxiety Disorder Therapeutics Product Portfolio
  12. 7.2.5 Edgemont Pharmaceuticals, LLC Recent Developments
  13. 7.3 H. Lundbeck A/S
  14. 7.3.1 H. Lundbeck A/S Company Information
  15. 7.3.2 H. Lundbeck A/S Business Overview
  16. 7.3.3 H. Lundbeck A/S General Anxiety Disorder Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 H. Lundbeck A/S General Anxiety Disorder Therapeutics Product Portfolio
  18. 7.3.5 H. Lundbeck A/S Recent Developments
8 North America
  1. 8.1 North America General Anxiety Disorder Therapeutics Revenue (2021-2032)
  2. 8.2 North America General Anxiety Disorder Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America General Anxiety Disorder Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America General Anxiety Disorder Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America General Anxiety Disorder Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America General Anxiety Disorder Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America General Anxiety Disorder Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America General Anxiety Disorder Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America General Anxiety Disorder Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America General Anxiety Disorder Therapeutics Revenue by Country
  11. 8.6.1 North America General Anxiety Disorder Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America General Anxiety Disorder Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America General Anxiety Disorder Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe General Anxiety Disorder Therapeutics Revenue (2021-2032)
  2. 9.2 Europe General Anxiety Disorder Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe General Anxiety Disorder Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe General Anxiety Disorder Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe General Anxiety Disorder Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe General Anxiety Disorder Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe General Anxiety Disorder Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe General Anxiety Disorder Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe General Anxiety Disorder Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe General Anxiety Disorder Therapeutics Revenue by Country
  11. 9.6.1 Europe General Anxiety Disorder Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe General Anxiety Disorder Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe General Anxiety Disorder Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China General Anxiety Disorder Therapeutics Revenue (2021-2032)
  2. 10.2 China General Anxiety Disorder Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China General Anxiety Disorder Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China General Anxiety Disorder Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China General Anxiety Disorder Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China General Anxiety Disorder Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China General Anxiety Disorder Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China General Anxiety Disorder Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China General Anxiety Disorder Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia General Anxiety Disorder Therapeutics Revenue (2021-2032)
  2. 11.2 Asia General Anxiety Disorder Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia General Anxiety Disorder Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia General Anxiety Disorder Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia General Anxiety Disorder Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia General Anxiety Disorder Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia General Anxiety Disorder Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia General Anxiety Disorder Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia General Anxiety Disorder Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia General Anxiety Disorder Therapeutics Revenue by Country
  11. 11.6.1 Asia General Anxiety Disorder Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia General Anxiety Disorder Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia General Anxiety Disorder Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA General Anxiety Disorder Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA General Anxiety Disorder Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA General Anxiety Disorder Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA General Anxiety Disorder Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA General Anxiety Disorder Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA General Anxiety Disorder Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA General Anxiety Disorder Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA General Anxiety Disorder Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA General Anxiety Disorder Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA General Anxiety Disorder Therapeutics Revenue by Country
  11. 12.6.1 SAMEA General Anxiety Disorder Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA General Anxiety Disorder Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA General Anxiety Disorder Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst